for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Qiagen NV

QIA.DE

Latest Trade

47.70EUR

Change

0.13(+0.27%)

Volume

643,035

Today's Range

47.09

 - 

47.99

52 Week Range

37.38

 - 

51.56

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
47.57
Open
47.50
Volume
643,035
3M AVG Volume
15.07
Today's High
47.99
Today's Low
47.09
52 Week High
51.56
52 Week Low
37.38
Shares Out (MIL)
227.34
Market Cap (MIL)
10,918.60
Forward P/E
21.62
Dividend (Yield %)
--

Next Event

Qiagen NV at Berenberg European Conference

Latest Developments

More

Qiagen And Diasorin Widen Access To Latent TB Testing In U.S., Gain FDA Approval

Qiagen NV Reports Q3 Diluted EPS Of $0.57

Qiagen Receives U.S. FDA EUA QIAreach SARS COV-2 Antigen Test

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Qiagen NV

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Industry

Biotechnology & Drugs

Contact Info

Hulsterweg 82

5912 PL

Netherlands

+31.77.3556600

https://www.qiagen.com/

Executive Leadership

Lawrence A. Rosen

Independent Chairman of the Supervisory Board

Thierry Bernard

Chief Executive Officer, Managing Director, Member of the Executive Board

Roland Sackers

Managing Director, Chief Financial Officer, Member of the Executive Committee

Metin Colpan

Independent Member of the Supervisory Board

Ross L. Levine

Independent Member of the Supervisory Board

Key Stats

2.27 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.5K

2019

1.5K

2020

1.9K

2021(E)

2.2K
EPS (USD)

2018

1.340

2019

1.430

2020

2.150

2021(E)

2.501
Price To Earnings (TTM)
21.04
Price To Sales (TTM)
5.50
Price To Book (MRQ)
4.06
Price To Cash Flow (TTM)
15.52
Total Debt To Equity (MRQ)
64.38
LT Debt To Equity (MRQ)
52.05
Return on Investment (TTM)
12.35
Return on Equity (TTM)
10.09

Latest News

Latest News

Qiagen lifts annual forecast as COVID testing boosts third-quarter profit

Qiagen on Wednesday raised its full-year forecasts for profit and revenue, with higher demand for its non-coronavirus products as well COVID-19 tests helping the U.S.-German genetic testing specialist beat quarterly profit expectations.

Qiagen Q3 profit surges on COVID-19 testing demand

U.S.-German genetic testing specialist Qiagen reported a surge in third-quarter profit on Wednesday, boosted by higher demand for its coronavirus tests amid a rise in infections due to the fast-spreading Delta variant.

European shares end at record high on strong earnings

European shares finished at a record high on Wednesday following a strong batch of quarterly earnings, while heavyweight mining stocks recovered from recent losses as commodity prices rose.

3M, Qiagen to comply with Biden's COVID-19 vaccination, test mandate

3M Co, the biggest U.S. producer of N95 masks, and German genetic testing specialist Qiagen said separately on Friday that they will comply with the Biden administration's new COVID-19 vaccination and testing mandate for workplaces.

Qiagen supports White House COVID-19 vaccination, test mandate

German genetic testing specialist Qiagen said on Friday it supported Biden administration's new COVID-19 vaccination and testing mandate for workplaces.

Porsche, Puma to join Germany's DAX as index expands

German carmaker Porsche and sportswear maker Puma will join the nation's premier DAX stock index, as it expands to 40 from 30 companies in the biggest overhaul of its 33-year history, the exchange operator Deutsche Boerse said on Friday.

FACTBOX-Key changes in shake-up of Germany's blue-chip DAX index

German exchange operator Deutsche Boerse is due to announce new entrants to the blue-chip DAX index on Friday, part of the index's biggest ever overhaul https://www.reuters.com/article/us-deutsche-boerse-dax-idUKKBN2840J0.

PRESS DIGEST-Financial Times - Aug 30

The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

Qiagen shares hit 21-year high as COVID-19 test demand revives

German genetic testing specialist Qiagen is seeing demand for its COVID-19 tests firming up again, leading it to believe that sagging demand in July was temporary, Chief Financial Officer Roland Sackers said on Friday.

European shares ease from peak; banks, miners boost UK stocks

European stocks eased from all-time highs on Tuesday ahead of a key U.S. inflation reading, but British banks kept UK's FTSE 100 afloat after a central bank move to scrap curbs on dividends.

European shares ease from peak, London outperforms on banking boost

European stocks eased from all-time highs on Tuesday, ahead of a key U.S. inflation reading, but British banks kept UK's FTSE 100 afloat after a central bank move to scrap curbs on dividends.

Qiagen cuts outlook on weaker COVID-19 testing trends, shares fall

U.S.-German genetic testing company Qiagen NV reported higher-than-expected second-quarter earnings on Monday but lowered its outlook on weaker demand for COVID-19 tests, sending its shares lower in New York.

Testmaker’s activist spat risks M&A rerun

(The author is a Reuters Breakingviews columnist. The opinions expressed are their own.)

Qiagen first-quarter profit tops expectations on growth in non-COVID-19 products

U.S.-German genetic testing company Qiagen NV reported slightly better-than-expected quarterly earnings on Monday as sales growth in its non-coronavirus products added to high demand for COVID-19 tests.

Qiagen reports Q1 beat thanks to growth in non-COVID-19 products

U.S.-German genetic testing specialist Qiagen reported slightly better-than-expected quarterly earnings on Monday as sales growth for non-coronavirus products added to high demand for its COVID-19 testing solutions.

Qiagen receives FDA emergency approval for coronavirus PCR test

Genetic testing specialist Qiagen received emergency use authorization for a new coronavirus test from the U.S. drugs regulator FDA, it said on Monday.

Qiagen is interested in organic growth and acquisitions - CEO

Genetic testing specialist Qiagen's Chief Executive Thierry Bernard said the company is interested in organic growth and "bolt-on" acquisitions, when asked about recent merger and acquisition speculation during a results conference call on Wednesday.

Qiagen reports fourth-quarter beat on strong demand for COVID-19 testing

U.S.-German genetic testing company Qiagen reported better-than-expected quarterly earnings on Tuesday, citing very strong demand for COVID-19 testing combined with improvements in non-COVID-19 areas of its portfolio.

UPDATE 1-Qiagen reports Q4 beat on strong demand for COVID-19 testing

U.S.-German genetic testing company Qiagen reported better-than-expected quarterly earnings on Tuesday, citing very strong demand for COVID-19 testing combined with improvements in non-COVID-19 areas of its portfolio.

Breakingviews - Capital Calls: Virus testing M&A fails smell test

Concise insights on global finance in the Covid-19 era.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up